Adial Pharmaceuticals, Inc. has adjourned its 2026 Annual Meeting of Stockholders for a second time regarding four specific proposals, citing the absence of a required Nasdaq conditional approval. The company filed an 8-K with the Securities and Exchange Commission on October 15, 2026, to disclose that it reconvened the meeting that day but chose to extend the delay for Proposals 3, 4, 5, and 6. The remaining proposals had already been voted upon at the initial convening in September. The next scheduled reconvene date for the pending items is October 26, 2026.
The initial delay stemmed from the company's need to secure Nasdaq's conditional approval of an Initial Listing Application related to the proposals presented at the annual meeting. Adial Pharmaceuticals originally convened the meeting on September 17, 2026. At that time, the company moved forward with votes on Proposals 1, 2, 7, 8, 9, 10, 11, and 12. It adjourned the meeting in part for Proposals 3, 4, 5, and 6 until October 1, 2026, to allow additional time to obtain the necessary Nasdaq approvals.
On October 1, 2026, the company reconvened the meeting for the pending proposals but exercised its authority to adjourn them again until October 15, 2026. The company filed its definitive proxy statement on Schedule 14A with the SEC on August 24, 2026, which details all proposals subject to stockholder vote. The record date for the annual meeting remains August 17, 2026.
The company stated that polls remain open for Proposals 3, 4, 5, and 6. Stockholders who have already submitted proxies with votes on these proposals do not need to take further action unless they wish to change their vote. No changes have been made to the proposals themselves. The adjourned meeting will reconvene on October 26, 2026, at 8:30 a.m. Eastern Time at the company's offices at 650 Peter Jefferson Parkway, Suite 230, Charlottesville, Virginia.
Cary J. Claiborne, President and Chief Executive Officer of Adial Pharmaceuticals, signed the report on October 16, 2026. The company noted that this document may be deemed solicitation material for the annual meeting. Stockholders are urged to read the definitive proxy statement and other relevant documents filed with the SEC before making voting decisions. These materials are available free of charge at www.sec.gov.